Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective.

Methods

A Markov model with three-state was employed to simulate recurrent or metastatic cervical cancer patients who were administered either tisotumab vedotin or investigator's choice of chemotherapy based on the phase III, open-labeled innovaTV 301 randomized clinical trial. The data on cost and health preferences were collected from the literature.

Results

Tisotumab vedotin generated an additional 0.25 quality-adjusted life-years (QALYs) compared to chemotherapy, but at an additional cost of $206,779. This results in incremental cost-effectiveness ratios of $839,107.88 per QALY. The results of

SUBMITTER: Huo G 

PROVIDER: S-EPMC11390250 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature